Shots:

• The P-II trial assessed safety & efficacy of islatravir (2mg) + lenacapavir (300mg, oral, QW) in virologically suppressed HIV adults (n=104, median age: 40yrs.) on Biktarvy or they may continue daily Biktarvy
• Study showed a viral suppression (HIV-1 RNA <50 copies/mL) rates of 94.2% with the combination (none of them had a viral load of ≥50 copies/mL) and 94.2% vs 92.3% in those who switched to the regimen vs continued Biktarvy at 48wks. The primary data from wk.24 were presented earlier at CROI 2024
• The islatravir and lenacapavir regimen, as a fixed-dose, is also being investigated under two P-III trials (NCT06630286 & NCT06630299) in virologically suppressed people with HIV

Ref: Merck | Image: Merck & Gilead

Related News:- Gilead and Merck Report Results from the P-II Clinical Evaluation of Islatravir + Lenacapavir for HIV

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com